Drug
Tysabri And Avonex
Tysabri And Avonex: highest development phase Post-Market, developed by Biogen. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| TYSABRI and AVONEX NCT00771043 | Post-Market | Relapsing-remitting Multiple Sclerosis |
Latest
No recent events.
Follow Tysabri And Avonex on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.